Abstract
The clinical and epidemiologic management of the SARS-CoV-2 pandemic is critically dependent on molecular assays with short turn-around time. We validated the novel Xpert Xpress SARS-CoV-2 assay using a commercial nucleic acid testing (Roche Cobas 6800). We found an excellent concordance over a range of SARS-CoV-2 loads and across established human coronaviruses.
Keywords:
COBAS 6800; COVID-19; Diagnostics; GeneXpert; NAT; PCR; Respiratory infection; SARS-CoV-2; Viruses.
Copyright © 2020. Published by Elsevier B.V.
MeSH terms
-
Betacoronavirus / genetics
-
Betacoronavirus / isolation & purification*
-
COVID-19
-
COVID-19 Testing
-
Clinical Laboratory Techniques / instrumentation
-
Clinical Laboratory Techniques / methods*
-
Clinical Laboratory Techniques / standards
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / virology*
-
Diagnostic Tests, Routine
-
Humans
-
Nasopharynx / virology
-
Pandemics
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / virology*
-
Polymerase Chain Reaction / instrumentation
-
Polymerase Chain Reaction / methods
-
Reproducibility of Results
-
SARS-CoV-2
-
Sensitivity and Specificity